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Abstract
Parkinson’s disease is a neurodegenerative disorder that currently impacts 6.1 million people globally. Although it has different
presentations, its core features are tremors, postural instability, bradykinesia (slowing of movement), and psychological disabilities
such as mood disorders and cognitive decline. A primary treatment is Levodopa, but it has limited success. A promising treatment
called Deep Brain Stimulation (DBS) has been shown to induce significant improvements in motor skills where Levodopa has
failed to help. Deep Brain Stimulation works via implanted electrodes. It has been used successfully in many studies to decrease
motor issues associated with Parkinson’s, but potential side effects pose a problem. Overall though, DBS is a promising field of
study in the ongoing attempt to find treatments for Parkinson’s disease, especially as we identify specific aspects of DBS that
improve the risk to benefit ratio. This review of the current literature was conducted in order to determine the efficacy and safety
of DBS as a treatment for PD.
Introduction
Parkinson’s disease (PD) was first described medically by
James Parkinson in 1817. Jean-Martin Charcot continued
discovering more about Parkinson’s disease in the mid
1800’s and was instrumental in further developing the
definition of Parkinson’s by stating what made it a unique
disorder (Goetz, 2011). Over the years, Parkinson’s disease
has been a subject of research, and although there is still
no cure, there are many treatments aimed at relieving the
symptoms. There are very effective pharmaceutical interventions available, such as the drug Levodopa. Other
treatments range from traditional (lesioning of brain areas
associated with PD symptoms) to new and experimental
(implantation of human parthenogenetic stem cell-derived
neural stem cells in animals with PD symptoms [Gonzalez,
et al. 2016]). This paper will focus on discussing Parkinson
Disease, and the use of deep brain stimulation to treat it.
It will also seek to answer questions regarding the mechanisms, effectiveness, and drawbacks of DBS.
Methods
Available literature on the topics of Parkinson’s Disease
and Deep Brain Stimulation were reviewed using the
search function on the Touro Library website, and by utilizing Google and Google Scholar.
Discussion
Parkinson’s disease impacted 6.1 million people globally in
2016, and the rate keeps rising, as seen from the fact that
only 2.5 million people had Parkinson’s in 1990 (Dorsey,
et al. 2018). Age is one of the most important risk factors,
as more than 75% of people with Parkinson’s developed it
after the age of 65 (Bloem, et al. 2021), although people
can develop it at a young age if they have a genetic predisposition. The main genes associated with Parkinson’s
disease are the SNCA, LRRK2, PRKN, PINK1, and GBA
genes. Other risk factors associated with Parkinson’s are
head injuries and lifestyle factors, such as lack of exercise
and exposure to toxins. Interestingly, smoking has been
shown to be inversely related to developing Parkinson’s

disease, although it is unclear if the connection is correlational or causal (Bloem, et al 2021).
Parkinson’s presents with many motor and non-motor
symptoms. Prominent motor symptoms include bradykinesia, or slowness of movements, tremor, postural instability and rigidity. Dyskinesia, or impairment of movements, is another significant side effect that may develop
with long-term treatment with Levodopa, and may cause
involuntary movements that severely impact a person.
There are also many non-motor symptoms associated
with Parkinson’s, such as dementia, depression, and dysregulation of a person’s sleep cycle.
Buildup of α-synuclein in Lewy bodies and neurites is
the pathological defining feature of Parkinson’s disease.
New studies suggest that a similar accumulation occurs
in other tissues such as skin cells, which may be a helpful
predictor of onset of Parkinson’s as that tissue is much
more accessible than brain tissue (Bloem, et al 2021).
Currently PD is diagnosed clinically, based on symptoms.
It may be difficult to diagnose, as the symptoms may be
similar to other diseases.
Parkinson’s is caused by a decrease of the neurotransmitter dopamine, which is caused by the death of cells
in the substantia nigra. This is the source of dopamine
production in the brain, and as cells die less dopamine is
produced. Dopamine is integral in regulating movement.
Loss of cells is normal with aging, but accelerated loss
leads to Parkinson’s; 50-60% loss indicates the onset of
symptoms (Johns Hopkin’s Medicine).
Replacing dopamine is not as simple as taking supplementary pills, as dopamine cannot enter the brain.
Currently, a primary treatment for Parkinson’s is levodopa, a drug that is converted to dopamine in the brain.
However, some people don’t respond to levodopa, or
become resistant to it over time, or may experience fluctuations in their responses. For people who are not
receiving optimal results with pharmaceutical therapies,
neurosurgical treatments such as deep brain stimulation,
or DBS, may be effective in controlling motor symptoms.
(Bloem, et al 2021)
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As explained by the Mayo Clinic, the surgical portion
of DBS takes place in two parts; first, the brain is mapped
out via screening tests such as an MRI, and electrodes are
surgically implanted in the targeted areas. Later, in a different procedure, the battery source for the electrodes,
the pulse generator, is implanted near the collarbone and
connected to the electrodes via wires. In future doctor
visits, the patient undergoes testing to determine the correct level of stimulation needed. Once all this is in place,
ongoing supervision and tweaking of the signaling is done
via a special remote control. A person may have ongoing
stimulation, or it may be turned on and off via remote as
needed. (Mayo Clinic, 2021).
Improvement times of symptoms vary, and are partly based on the area where the electrodes are located.
For example, with subthalamic nucleus deep brain stimulation (STN DBS), tremors are relieved after seconds
of DBS activation, rigidity and bradykinesia are relieved
after minutes to hours, and axial symptoms may take
days to be relieved. The return of symptoms once the
electrode is deactivated mirrors the time of activation;
for example, tremors return in minutes. This suggests
that the improvements are due to different mechanisms.
Quick relief of symptoms may be due to instant release
of neurotransmitters, while long term relief may at least
partly be due to plasticity or remodeling of the brain
(Herrington, et al 2016)
DBS replaced lesioning operations, and in comparison, caused little or no tissue damage, and is therefore
reversible (Groiss et al, 2009). In a postmortem case
study done on the brain of a 21 year old patient who
underwent DBS in the anterior thalamus for epilepsy, it
was found that the DBS caused little tissue damage. The
patient died unexpectedly 8 months after surgery, and an
autopsy showed his death was an unexpected result of
epilepsy. When studying his brain posthumously, it was
found that DBD caused only mild tissue reaction and did
not cause significant damage (Pilitsis, et. al. 2008)
The two primary target areas for DBS in people with
PD are the subthalamic nucleus (STN) and globus pallidus
interna (GPi). In a study, 299 patients were randomly
assigned to either STN or GPi DBS. One hundred and
fifty-two patients received GPi DBS, and 147 patients underwent STN DBS. The two groups started with similar
baseline characteristics, except for minor differences in
areas such as emotional well-being, social support, and
cognition. Of the original group of patients, only 279 patients completed a 6-month evaluation.
At 24 months, it was found that there was no significant difference of motor symptom outcomes (based on
the UPRDS III) between the two groups. There was a
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reduction of 11.8 in the group that received DBS-STN and
a reduction of 10.7 points in the group that received STNDBS. When the participants took the PDQ-39 (Parkinson
daily questionnaire) to test quality of life, both study groups
indicated improvement in 6 of the 8 subscales. Social support was slightly increased for the group with STN DBS,
and decreased for GPi DBS, but no significant differences
were found between the two groups. They also had similar results when testing for neurocognitive function and
mood, but the group that received GPi DBS had slightly
better scores on the Beck Depression Inventory, and the
STN DBS group had a slight decline (P=.02).
Another finding from the study was that patients who
received STN DBS were able to reduce their dopaminergic medication, as compared to patients who received
GPi DBS. Additionally, STN DBS has lower amplitudes
and pulse widths, which translates to lower power usage,
and ultimately less frequent replacement of the pulse
generator. This can contribute to lower therapy costs,
and decreased risk from surgical replacement of the pulse
generator (Follet, et al. 2010). This aspect is very important, as patients with Parkinson’s often have a hard time
with basic activities of daily living, and having to undergo
surgery every couple of years is a real hardship. Anything
that minimizes the amount of upkeep their hardware requires is an advantage.
In a study on the effect of STN DBS versus GPi DBS
specifically on action and rest tremors in PD, 88 patients
were studied in a final cohort; 57 patients underwent
STN DBS, and 31 underwent GPi. They found that there
was no significant difference in how the two forms of
DBS treated tremors, but that STN DBS was effective
more quickly. At 6 months post treatment, the patients
who underwent STN DBS had more relief from tremor
than the GPi DBS patients, but at the 12-month checkup
the GPi group had caught up (Wong, et al. 2020).
Another study analyzed 25 patients who underwent
either STN or GPi DBS. Both on and off medication,
it was shown that there is not a significant difference in
outcomes between the two groups. After 12 months,
there was a 39 % improvement in motor scores in the
GPi group, and a 48% improvement in the STN group
(P<.001). Similar to results from the study above, after
twelve months of DBS the STN group had a reduction in
Levodopa of 38%, whereas the GPi group had a reduction
of only 3%. Additionally, it was found that STN was more
effective in reducing bradykinesia than GPi DBS, but GPi
DBS may cause long term changes in dopaminergic systems (Anderson, et al. 2005).
Many studies have shown the positive effects of DBS
on motor symptoms of PD. In a metanalysis done on 38
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short term studies, STN DBS improved rigidity by 62%
and bradykinesia by 52% after 12 months. GPi DBS had
comparable results (Fasano, et al. 2012).
In a study done using the Deep Brain Stimulation for
Parkinson’s Disease Study Group on GPi DBS and STN
DBS, 96 patients underwent STN DBS, and 91 underwent
double blind evaluations and 6 months of follow up. It was
found that there was a significant relationship between
STN DBS therapeutic treatment and therapeutic effect
(p<.0001), with treatment resulting in a 43% mean improvement in motor symptoms based on ratings from the
UPDRS (Obeso, et al. 2001).
In the same study, forty-one patients received GPi DBS,
36 of whom underwent 6 months of follow up. Again,
there were significant effects associated with the treatment, (p<.0001) with a mean improvement of motor
symptoms based on the UPDRS of 32 percent. This suggests that STN DBS may be superior to GPi DBS, but
both have been shown to significantly improve the motor
symptoms of PD. Based on these results, it appears that
DBS is an optimal therapy to treat PD, and patients who
meet the criteria for it should be encouraged to explore
this option. When a person experiences impaired functioning due to PD symptoms, it may be difficult to regain that functioning even if symptoms are reduced. We
should be treating PD proactively, and offering treatments
such as DBS as early as possible.
The previous studies discussed short term results of
DBS on PD. Paul Krack et al conducted a 5 year follow
up on 49 patients treated with STN DBS. When not taking medication, patients’ motor symptoms improved (as
rated by part III of the UPDRS) from the base line value
by 66 percent after the first year, 59 percent after the
third year and by 54 percent after 5 years. Additionally,
before surgery 35 of the 49 patients had dystonia when
not taking medication, and after a year of receiving DBS
only 8 out of 43 had dystonia, and at 5 years only 14 out
of 42 patients had it. However, when the patients were
taking medication, there was no improvement. In fact 5
years post surgery the motor functions had decreased
overall, with worsening of postural stability and freezing
gait (Krack, et al. 2003). This study had no control group,
but it would be interesting to see these results compared
to results of patients treated only with pharmaceutical
interventions.
There are a few accepted models to explain the pathophysiology of PD. One is the firing rate model. Dopamine
triggers excitatory inputs to striatal direct pathway neurons projecting to the GPi, and inhibitory inputs to the
indirect pathway neurons; loss of dopamine reduces both
of these signals, increasing firing rates of the GPi and SNr

(substantia nigra pars reticulata) neurons. Lesioning of
the GPi or STN had beneficial effects on PD, backing up
this theory. Alternatively, impaired functioning may due
to firing patterns, or faulty oscillatory circuits, not disturbed firing rates (Chiken, Nambu, 2014). The brain is
not composed of one complete oscillatory circuit; it is
composed of many circuits, small and large, parallel and
working together. When there is pathological oscillatory
activity, especially beta band oscillations, in the circuit between the cortex, the basal ganglia, and the cerebellum, it
may contribute to the motor symptoms of PD. A future
area of focus therefore may be on DBS aimed specifically
at disrupting these abnormal beta band oscillations, rather than general continuous DBS (Herrington, et al. 2020)
When dopamine is low, as in PD, there is increased oscillatory movement in the basal ganglia. This in turn disables
individual neurons, which can no longer properly process
or pass on motor-related information.
Initially DBS was thought to inhibit neurons near the
electrode. This theory was backed up by the fact that
chemical inhibition of the STN or GPi also reduced
Parkinson motor dysfunction, perhaps by release of the
neurotransmitter GABA. However, currently there are
many theories proposed for the exact mechanism of DBS.
One that is supported by research is that DBS introduces
a new electrical circuit that drowns out the faulty electrical signals in a PD patient’s brain (Herrington, et al. 2020).
A study examined the impact of adaptive DBS (a form
of DBS that utilizes feedback from neuronal activity to
activate more selectively) on beta band bursts. The study
was done on 13 patients who underwent adaptive DBS
that broke up long beta bursts. The researchers found
that Parkinson symptoms were relieved with short beta
bursts, regardless of the frequency of the bursts, and intensified with long bursts. This effect occurs with conventional DBS as well, but with a different mechanism
(Tinkhauser, et al. 2017).
Although DBS has been shown to improve motor
symptoms in patients with Parkinson’s disease, there is
still concern regarding its effect on non-motor functions
such as cognitive and psychiatric functioning. In a study,
60 patients were assigned to either SNT or GPi DBS,
and 63 people were assigned to other types of treatment.
The participants underwent cognitive and psychiatric
assessment 6 months after the treatment. Criteria for
participation were having a diagnosis of Parkinson’s for at
least 5 years, being below 75 years in age, having no prior
or current psychiatric disorders, and being prepared to
undergo neurosurgery. The participants who received
DBS had bilateral stereotactic surgery, with a baseline
pulse of 60 μs at 130 Hz with individualized adjustments.
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The group who received alternate medical treatment
received medication such as Levodopa. Cognitive tests
were picked that focused on skills often affected by PD,
such as cognitive skills, and had less motor skills aspects. Tests such as the Mattis dementia rating scale, the
Wechsler adult intelligence test, and modified versions
of the Stroop test were utilized. Participants’ emotional
states were measured by tests such as the Beck depression inventory and the Beck anxiety inventory. Quality
of life was also assessed, with tests like the Parkinson’s
Disease questionnaire.
Results showed a significant improvement in motor
skills and quality of life post DBS treatment, as compared
to the group that received only medication. Overall cognitive functions were not impaired in participants who
received DBS, but there were specific areas of decline.
For example, based on the Mattis dementia rating scale,
participants from both treatment plans had similar results
when excluding verbal scoring, but when verbal scoring
was factored in, the group who received DBS had worse
results. Seven participants had reduction of more than
2 SD. By comparison, four participants from the other
group had reduction of more than 2 SD. When excluding
verbal fluency however, only 3 DBS participants were further away than 2 SD, as opposed to 4 participants from
the other group. People from the DBS group also showed
reduced performance in the Stroop tests.
The study demonstrated that people who received DBS
exhibited no significant decline in cognitive or psychiatric
functioning, with the possible exception of verbal fluency.
They even experienced an improvement in areas such as
anxiety, although that may be due to other factors such as
the nature of the questions on the test (Witt, et al. 2008).
These results have also been shown in a review which
analyzed studies published in England on patients with
PD who underwent STN or GPi DBS. The studies included neuropsychological testing, and included at least
5 subjects who were followed for at least 3 months after
their operations. The authors concluded that although
different studies show different results, overall cognitive
functioning decline is rare for patients that undergo DBS,
and any change found is probably subtle. In addition, taking into account the significant improvements in motor
function, even if DBS may be associated with decreased
cognitive functions in some studies, it is still shown to
improve overall quality of life (Mehanna, et al. 2017).
Another potential concern with DBS is the risk of
hardware complications, or other risks associated with
the surgery. In another study, 478 patients who had received DBS at a single medical center were retrospectively analyzed. Forty-one people had died. The biggest
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cause of death was pneumonia, with trouble swallowing
being another leading cause of death. Two of the deaths
were due to hemorrhaging the week following surgery.
Only 22 people reported hardware troubles, including rejection, infection, and hardware failure. This study seems
to indicate that hardware problems are not a significant
issue in patients who undergo DBS, and other issues such
as pneumonia and trouble swallowing are larger risk factors for patients with PD (Zhang, et al. 2017).
Conclusion
Parkinson’s disease is a neurodegenerative disorder that
impacts an increasing number of people. Although it can
often be treated with medications such as Levodopa,
there are times when medication alone is not effective.
DBS can cause a significant improvement in motor symptoms over a long period of time. The side effects are
found to be minimal. DBS is currently a very good treatment option for people struggling with PD symptoms
that cannot be controlled by medication alone. As we
do more research and improve DBS, it will become even
more effective and safe.
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